You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Claims for Patent: 11,324,753

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,324,753

Title:	Method of treatment of attention deficit/hyperactivity disorder (ADHD)
Abstract:	The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
Inventor(s):	Christopher D. Breder
Assignee:	Supernus Pharmaceuticals Inc
Application Number:	US15/615,423
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,324,753
Patent Claims:	1. A method of antagonizing 5-HT7 and 5HT1B receptor activity in a patient suffering from ADHD, consisting of administering to the patient in need thereof a therapeutically effective amount of viloxazine, wherein the administration antagonizes both receptors. 2. The method of claim 1, wherein the therapeutically effective amount is from about 20 to about 800 mg a day. 3. The method of claim 1, wherein the therapeutically effective amount is from about 10 to about 600 mg a day. 4. The method of claim 3, wherein the therapeutically effective amount is from about 150 to about 400 mg a day. 5. The method of claim 4, wherein the therapeutically effective amount is from 150 to 300 mg a day. 6. The method of claim 1, which provides an improved adverse effect profile. 7. The method of claim 1, wherein the patient is a human child. 8. The method of claim 1, wherein the patient further suffers from anxiety, depression, or bipolar disorder. 9. The method of claim 1, wherein the patient further suffers from obsessive compulsive disorder, Tourette's Syndrome, or Post Traumatic Stress Disorder.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.